Advertisement

Candidiasis

  • M. Altay Atalay
Chapter

Abstract

Candidiasis frequently occurs in newborns, in immune-deficient people like acquired immunodeficiency syndrome patients, and in people being treated with broad-spectrum antibiotics. It is manifested by the acute and/or chronic infections of the skin, mucosa, internal organs, and systems, which are caused by a genus of yeast called Candida species. It is mostly due to Candida albicans, while other species such as C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei are increasingly isolated. Each of these organisms has unique virulence potential, antifungal susceptibility, and epidemiology. Recently, another species of Candida, C. auris, has been introduced, presenting with multidrug resistance and a high mortality rate as a dangerous health threat in some countries. Unlike superficial Candida infections, invasive candidiasis is an important healthcare-related infection that can affect the blood, heart, brain, eyes, bones, and other parts of the body.

Keywords

Candidiasis Candida albicans Non-albicans Candida Superficial Candida infections Invasive candidiasis 

Abbreviations

AIDS

Acquired immunodeficiency syndrome

CMC

Chronic mucocutaneous candidiasis

CNS

Central nervous system or Coagulase-negative staphylococci

CSF

Cerebrospinal fluid

CT

Computed tomography

CVC

Central venous catheter

DM

Diabetes mellitus

ESCMID

European Society of Clinical Microbiology and Infectious Diseases

GIT

Gastrointestinal tract

HIV

Human immunodeficiency virus

IC

Invasive candidiasis

ICU

Intensive care unit

IDSA

Infectious Diseases Society of America

IL

Interleukin

MRI

Magnetic resonance imaging

NAC

Non-albicans Candida

NPV

Negative predictive value

PPV

Positive predictive value

TPN

Total parenteral nutrition

References

  1. Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev. 2010;23:253–73.CrossRefGoogle Scholar
  2. Aldress K, Al Shaalan M, Memish Z, Alola S, Bannatyne R. Candida meningitis in children. Report of two cases. J Chemother. 2000;12:339–44.CrossRefGoogle Scholar
  3. Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56:1724–32.CrossRefGoogle Scholar
  4. Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care. 2010;16:445–52.CrossRefGoogle Scholar
  5. Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One. 2011;6:e24198.CrossRefGoogle Scholar
  6. Block AA, Thursky KA, Worth LJ, Slavin MA. Thrombolytic therapy for management of complicated catheter-related Candida albicans thrombophlebitis. Intern Med J. 2009;39:61–3.CrossRefGoogle Scholar
  7. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18:S19–37.CrossRefGoogle Scholar
  8. Correia A, Sampaio P, James S, Pais C. Candida bracarensis, sp. nov., a novel anamorphic yeast species phenotypically similar to Candida glabrata. Int J Syst Evol Microbiol. 2006;56:313–7.CrossRefGoogle Scholar
  9. Cowen LE, Sanglard D, Howard SJ, Rogers PD, Perlin DS. Mechanisms of antifungal drug resistance. Cold Spring Harb Perspect Med. 2014;5:a019752.CrossRefGoogle Scholar
  10. Cuenca-Estrella M, Verweij PE, Arendrup MC, Arikan-Akdagli S, Bille J, Donnelly JP, Jensen HE, Lass-Flörl C, Richardson MD, Akova M, Bassetti M, Calandra T, Castagnola E, Cornely OA, Garbino J, Groll AH, Herbrecht R, Hope WW, Kullberg BJ, Lortholary O, Meersseman W, Petrikkos G, Roilides E, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect. 2012;18:S9–18.CrossRefGoogle Scholar
  11. Das I, Nightingale P, Patel M, Jumaa P. Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK. Int J Infect Dis. 2011;15:e759–63.CrossRefGoogle Scholar
  12. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15:167–93.CrossRefGoogle Scholar
  13. Drummond RA, Lionakis MS. Candidiasis of the central nervous system in neonates and children with primary immunodeficiencies. Curr Fungal Infect Rep. 2018;12:92–7.CrossRefGoogle Scholar
  14. Einarsdóttir HM, Danielsen R, Gottfredsson M. Successful treatment of Candida glabrata myocarditis with voriconazole. Scand J Infect Dis. 2002;34:778–80.CrossRefGoogle Scholar
  15. Fernández-Ruiz M, Aguado JM, Almirante B, Lora-Pablos D, Padilla B, Puig-Asensio M, Montejo M, García-Rodríguez J, Pemán J, Ruiz Pérez de Pipaón M, Cuenca-Estrella M, CANDIPOP Project; GEIH-GEMICOMED (SEIMC); REIPI. Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis. 2014;58:1413–21.CrossRefGoogle Scholar
  16. Garcia-Cuesta C, Sarrion-Pérez MG, Bagán JV. Current treatment of oral candidiasis: a literature review. J Clin Exp Dent. 2014;6:e576–82.CrossRefGoogle Scholar
  17. Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis. 2005;41:e27–8.CrossRefGoogle Scholar
  18. Glockner A. Recurrent candidaemia and pacemaker wire infection with Candida albicans. Mycoses. 2011;54:S20–3.CrossRefGoogle Scholar
  19. Hope WW, Castagnola E, Groll AH, Roilides E, Akova M, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Cornely OA, Cuenca-Estrella M, Donnelly JP, Garbino J, Herbrecht R, Jensen HE, Kullberg BJ, Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson MD, Verweij PE, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect. 2012;18:S38–52.CrossRefGoogle Scholar
  20. Janniger CK, Schwartz RA, Szepietowski JC, Reich A. Intertrigo and common secondary skin infections. Am Fam Physician. 2005;72:833–8.PubMedGoogle Scholar
  21. Kakati B, Kotwal A, Biswas D, Sahu S. Fluconazole resistant Candida oesophagitis in immunocompetent patients: is empirical therapy justifiable? J Clin Diagn Res. 2015;9:16–8.Google Scholar
  22. Kohli R, Hadley S. Fungal arthritis and osteomyelitis. Infect Dis Clin North Am. 2005;19:831–51.CrossRefGoogle Scholar
  23. Kontoyiannis DP, Reddy BT, Torres HA, Luna M, Lewis RE, Tarrand J, Bodey GP, II R. Pulmonary candidiasis in patients with cancer: an autopsy study. Clin Infect Dis. 2002;34:400–3.CrossRefGoogle Scholar
  24. Lastauskienė E, Zinkevičienė A, Girkontaitė I, Kaunietis A, Kvedarienė V. Formic acid and acetic acid induced a programmed cell death in pathogenic Candida species. Curr Microbiol. 2014;69:303–10.CrossRefGoogle Scholar
  25. León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, Garnacho-Montero J, León MA, EPCAN Study Group. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006;34:730–7.CrossRefGoogle Scholar
  26. Loo DS. Cutaneous fungal infections in the elderly. Dermatol Clin. 2004;22:33–50.CrossRefGoogle Scholar
  27. Lortholary O, Petrikkos G, Akova M, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, Cornely OA, Cuenca-Estrella M, Donnelly JP, Garbino J, Groll AH, Herbrecht R, Hope WW, Jensen HE, Kullberg BJ, Lass-Flörl C, Meersseman W, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clin Microbiol Infect. 2012;18:S68–77.CrossRefGoogle Scholar
  28. Matthews RC. Pathogenicity determinants of Candida albicans: potential targets for immunotherapy? Microbiology. 1994;140:1505–11.CrossRefGoogle Scholar
  29. Mersequel KB, Nishikaku A, Rodrigues AM, Padovan AC, e Ferreira RC, de Azevedo Melo AS, Briones MR, Colombo AL. Genetic diversity of medically important and emerging Candida species causing invasive infection. BMC Infect Dis. 2015;15:57.CrossRefGoogle Scholar
  30. Naouri M, Mazer JM. Finger onychomycosis due to Candida tropicalis: short-pulsed Nd:YAG laser therapy. Ann Dermatol Venereol. 2013;140:610–3.CrossRefGoogle Scholar
  31. Nieto MC, Telleria O, Cisterna R. Sentinel surveillance of invasive candidiasis in Spain: epidemiology and antifungal susceptibility. Diagn Microbiol Infect Dis. 2015;81:34–40.CrossRefGoogle Scholar
  32. Oberoi JK. Invasive candidiasis. JIMSA. 2010;23:25–8.Google Scholar
  33. Odds FC. Molecular phylogenetics and epidemiology of Candida albicans. Future Microbiol. 2010;5:67–79.CrossRefGoogle Scholar
  34. Okada S, Puel A, Casanova JL, Kobayashi M. Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity. Clin Transl Immunology. 2016;5:e114.CrossRefGoogle Scholar
  35. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am. 2006;20:485–506.CrossRefGoogle Scholar
  36. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35.CrossRefGoogle Scholar
  37. Parra-Herran CE, Pelaez L, Sola JE, Urbiztondo AK, Rodriguez MM. Intestinal candidiasis: an uncommon cause of necrotizing enterocolitis (NEC) in neonates. Fetal Pediatr Pathol. 2010;29:172–80.CrossRefGoogle Scholar
  38. Perlin DS, Shor E, Zhao Y. Update on antifungal drug resistance. Curr Clin Microbiol Rep. 2015;2:84–95.CrossRefGoogle Scholar
  39. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:133–63.CrossRefGoogle Scholar
  40. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2500 clinical isolates of candida spp, including 315 isolates resistant to fluconazole. J Clin Microbiol. 2005;43:5425–7.CrossRefGoogle Scholar
  41. Pfalller MA, Andes DR, Diekema DJ, Horn DL, Reboli AC, Rotstein C, Franks B, Azie NE. Epidemiology and outcomes of invasive candidiasis due ton on-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004–2008. PLoS One. 2014;9:e101510.CrossRefGoogle Scholar
  42. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220:751–8.CrossRefGoogle Scholar
  43. Portocarrero JS, Cecilia EP, Corral O, Romero-Vivas J, Picazo JJ. The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis. 2000;37:169–79.CrossRefGoogle Scholar
  44. Rivoisy C, Vena A, Schaeffer L, Charlier C, Fontanet A, Delahaye F, Bouza E, Lortholary O, Munoz P, Lefort A, French Mycoses Study Group and Grupo de Apoyo al Manejo de las Endocarditis en España (GAMES). Prosthetic valve Candida spp. endocarditis: new insights into long-term prognosis—the ESCAPE study. Clin Infect Dis. 2018;66:825–32.CrossRefGoogle Scholar
  45. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis. 2002;2:73–85.CrossRefGoogle Scholar
  46. Sobel JD, Fisher JF, Kauffman CA, Newman CA. Candida urinary tract infections—epidemiology. Clin Infect Dis. 2011;52:433–6.CrossRefGoogle Scholar
  47. Sugar AM, Liu XP. Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles. Antimicrob Agents Chemother. 2000;44:2004–6.CrossRefGoogle Scholar
  48. Tavanti A, Davidson AD, Gow NA, Maiden MC, Odds FC. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol. 2005;43:284–92.CrossRefGoogle Scholar
  49. Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, Cornely OA, Donnelly JP, Garbino J, Groll AH, Hope WW, Jensen HE, Kullberg BJ, Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Cuenca-Estrella M, ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012;18:53–67.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • M. Altay Atalay
    • 1
  1. 1.Department of Medical MicrobiologyErciyes University School of MedicineKayseriTurkey

Personalised recommendations